Addictovigilance Centre, Montpellier University Hospital, Montpellier, France.
Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier, France.
Br J Clin Pharmacol. 2022 Oct;88(10):4646-4653. doi: 10.1111/bcp.15420. Epub 2022 Jun 8.
The study aim was to assess the abuse/misuse potential of second-generation antipsychotics (SGAPs) using VigiBase data. We extracted individual case safety reports of "Drug abuse, dependence and withdrawal" involving SGAPs up to June 2018. We assessed disproportionate reporting by calculating the information component, considering the lower end of the 95% credibility interval for the information component (IC ), and the proportional reporting ratio. We identified 1683 individual case safety reports recorded as "abuse, dependence and withdrawal" involving SGAPs, mainly quetiapine (n = 1089) and olanzapine (n = 209). The disproportional reporting indicators highlighted an association between "Drug abuse and dependence", and quetiapine, olanzapine and ziprasidone, as indicated by the IC (2.263, 0.259 and 1.051, respectively) and proportional reporting ratio values (3.929, 1.020 and 1.334, respectively). The abuse/misuse potential is confirmed for quetiapine and olanzapine and highlighted for the first time for ziprasidone. Physicians should consider these risks when prescribing these antipsychotics, especially to patients with history of drug abuse.
这项研究旨在使用 VigiBase 数据评估第二代抗精神病药物（SGAPs）的滥用/误用潜力。我们提取了截至 2018 年 6 月涉及 SGAPs 的“药物滥用、依赖和戒断”的个别案例安全报告。我们通过计算信息分量来评估不成比例的报告，同时考虑信息分量（IC）的下限和比例报告比。我们确定了 1683 份记录为“滥用、依赖和戒断”的个别案例安全报告，涉及 SGAPs，主要是喹硫平（n=1089）和奥氮平（n=209）。不成比例的报告指标突出了“药物滥用和依赖”与喹硫平、奥氮平和齐拉西酮之间的关联，这一点通过 IC（分别为 2.263、0.259 和 1.051）和比例报告比（分别为 3.929、1.020 和 1.334）的值表明。喹硫平和奥氮平的滥用/误用潜力得到证实，齐拉西酮的滥用/误用潜力首次得到强调。医生在开这些抗精神病药物时应考虑到这些风险，尤其是对有药物滥用史的患者。
